Schwartz Neil E, Albers Gregory W
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, 701 Welch Road, #B325, Palo Alto, CA 94304, USA.
Curr Neurol Neurosci Rep. 2008 Jan;8(1):29-34. doi: 10.1007/s11910-008-0006-1.
Antiplatelet agents are the medications of choice for preventing non-cardioembolic strokes. The diverse pathways involved in platelet function suggest the possibility of synergistic effects by combining various agents. In heart disease and in the setting of coronary artery stents, antiplatelet therapy with clopidogrel and aspirin has established benefits. Although it is tempting to extrapolate the benefits of this combination for stroke prevention, recent clinical trials have not borne this out. Unacceptable bleeding risks without additional efficacy weigh against the routine use of clopidogrel with aspirin for stroke prophylaxis. The combination of aspirin and extended-release dipyridamole has demonstrated superiority over aspirin in two large secondary stroke prevention trials.
抗血小板药物是预防非心源性卒中的首选药物。血小板功能涉及多种不同途径,这提示联合使用多种药物可能产生协同效应。在心脏病及冠状动脉支架置入的情况下,氯吡格雷与阿司匹林联合进行抗血小板治疗已证实具有益处。尽管推断这种联合用药对预防卒中有益很诱人,但近期的临床试验并未证实这一点。无额外疗效却存在不可接受的出血风险,这使得氯吡格雷与阿司匹林联合用于卒中预防的常规应用缺乏依据。在两项大型二级卒中预防试验中,阿司匹林与缓释双嘧达莫联合用药已证明比单用阿司匹林更具优势。